Role of High Dose Imatinib in BCR/ABL/Ph CML
نویسندگان
چکیده
s), Abstr. 2271.Rea, D.; Etienne, G.; Corm, S.; Cony-Makhoul, P.; Gardembas, M.; Legros, L.; Dubruille, V.;Hayette, S.; Mahon, F.X.; Cayuela, J.M. & Nicolini, F.E. (2009). Imatinib doseescalation for chronic phase-chronic myelogenous leukaemia patients in primarysuboptimal response to imatinib 400 mg daily standard therapy. Leukemia, Vol. 23(6), pp. 1193-1196.Rudzki, J. & Wolf, D. (2011). Dose escalation of imatinib in chronic-phase chronic myeloid leukemia patients: is it still reasonable? Expert Rev Hematol, Vol. 4 (2),pp. 153-159.Sawyers, C.L.; Hochhaus, A.; Feldman, E.; Goldman, J.M.; Miller, C.B.; Ottmann, O.G.; Schiffer, C.A.; Talpaz, M.; Guilhot, F.; Deininger, M.W.; Fischer, T.; O'Brien, S.G.;Stone, R.M.; Gambacorti-Passerini, C.B.; Russell, N.H.; Reiffers, J.J.; Shea, T.C.;Chapuis, B.; Coutre, S.; Tura, S.; Morra, E.; Larson, R.A.; Saven, A.; Peschel, C.;Gratwohl, A.; Mandelli, F.; Ben-Am, M.; Gathmann, I.; Capdeville, R.; Paquette,R.L. & Druker, B.J. (2002). Imatinib induces hematologic and cytogenetic responsesin patients with chronic myelogenous leukemia in myeloid blast crisis: results of aphase II study. Blood, Vol. 99 (10), pp. 3530-3539. Silver, R.T.; Cortes, J.; Waltzman, R.; Mone, M. & Kantarjian H. (2009). Sustained durabilityof responses and improved progression-free and overall survival with imatinibtreatment for accelerated phase and blast crisis chronic myeloid leukemia: long-term follow-up of the STI571 0102 and 0109 trials. Haematologica, Vol. 94 (5), pp.743-744.Sokal, J.E.; Cox, E.B.; Baccarani, M.; Tura, S.; Gomez, G.A.; Robertson, J.E.; Tso, C.Y.; Braun,T.J.; Clarkson, B.D. & Cervantes, F. (1984). Prognostic discrimination in "good-risk" chronic granulocytic leukemia. Blood, Vol. 63, pp. 789-799.Talpaz, M.; Silver, R.T.; Druker, B.J.; Goldman, J.M.; Gambacorti-Passerini, C.; Guilhot, F.; Schiffer, C.A.; Fischer, T.; Deininger, M.W.; Lennard, A.L.; Hochhaus, A.; Ottmann, O.G.; Gratwohl, A.; Baccarani, M.; Stone, R.; Tura, S.; Mahon, F.X.; FernandesReese, S.; Gathmann, I.; Capdeville, R.; Kantarjian, H.M. & Sawyers, C.L. (2002). Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood, Vol. 99 (6), pp. 1928-1937. Yeung, D.T.; Osborn, M.; White, D.L.; Branford, S.; Haswell, L.; Slader, C.; Issa, S.; Hiwas, D.K.; Hertzberg, M.S.; Schwarer, A.P.; Filshie, R.; Arthur, C.K.; Kwan, Y.L.; Forsyth, C.J.; Ross, D.M.; Mills, A.K.; Grigg, A. & Hughes T. (2010). Selective escalation of imatinib therapy and early switching to nilotinib in de novo chronic phae CML patients: interim results from the TIDEL-II Trial. Blood (ASH Annual Meeting Abstracts), Abstr. 209s), Abstr. 209
منابع مشابه
Evaluation of the Effect of Curcumin and Imatinib on BCR-ABL Expression Gene in Chronic Human k562 Cells
Background and Aims: Detection of overexpression in tumor-inhibiting genes provides valuable information for leukemia diagnosis and prognosis. Chronic myeloid leukemia (CML) is a stem cell disorder determined by a well-defined genetic anomaly involving BCR-ABL translocation in the Philadelphia chromosome. Curcumin is a chemo-preventive agent for the primary cancer targets, such as the breast, p...
متن کاملCoexistence of P190 and P210 BCR/ABL transcripts in chronic myeloid leukemia blast crisis resistant to imatinib
INTRODUCTION Philadelphia chromosome (Ph) is a hallmark of chronic myeloid leukemia (CML), which exists in more than 90% CML and in 3% to 40% acute lymphoblastic leukemia (ALL). CASE DESCRIPTION A 25-year-old man was diagnosed with CML in chronic phase. He first received treatment with hydroxyurea, achieving hematological remission and following imatinib mesylate for main treatment. A year la...
متن کاملSrc-family kinases in the development and therapy of Philadelphia chromosome-positive chronic myeloid leukemia and acute lymphoblastic leukemia
The BCR-ABL kinase inhibitor imatinib has shown significant efficacy in chronic myeloid leukemia (CML) and is the standard front-line therapy for patients in chronic phase. However, a substantial number of patients are either primarily refractory or acquire resistance to imatinib. While a number of mechanisms are known to confer resistance to imatinib, increasing evidence has demonstrated a rol...
متن کاملDasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.
BACKGROUND The BCR-ABL tyrosine kinase inhibitor imatinib is effective in Philadelphia chromosome-positive (Ph-positive) leukemias, but relapse occurs, mainly as a result of the outgrowth of leukemic subclones with imatinib-resistant BCR-ABL mutations. We evaluated dasatinib, a BCR-ABL inhibitor that targets most imatinib-resistant BCR-ABL mutations, in patients with chronic myelogenous leukemi...
متن کاملHigh-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia.
Imatinib mesylate (STI571) is effective in chronic phase chronic myelogenous leukemia (CML). However, most patients treated with 400 mg imatinib daily have variable levels of residual molecular disease. We treated 114 patients with newly diagnosed chronic phase CML with 400 mg imatinib twice daily. Overall, 109 patients (96%) had a major cytogenetic response (Philadelphia chromosome [Ph] < 35%)...
متن کاملAdaphostin-induced oxidative stress overcomes BCR/ABL mutation-dependent and -independent imatinib resistance.
The BCR/ABL kinase has been targeted for the treatment of chronic myelogenous leukemia (CML) by imatinib mesylate. While imatinib has been extremely effective for chronic phase CML, blast crisis CML and Ph+ acute lymphoblastic leukemia (ALL) are often resistant. In particular, mutation of the T315 residue in the bcr/abl activation loop renders cells highly resistant to imatinib and to second-ge...
متن کامل